Data acquisition and analysis

OTHER2 trials

Sponsors

GlaxoSmithKline

Conditions

Neoplasms, Urinary BladderPathologically Proven Stage I, II and III Non-Small Cell Lung Cancer (NSCLC)

Unknown Phase

Incidence of Expression of Tumor Antigens in Cancer Tissue From Patients With Pathologically Demonstrated Bladder Cancer

CompletedNCT01706185

GlaxoSmithKlineNeoplasms, Urinary Bladder

Start: 2008-01-15End: 2008-01-15Updated: 2018-07-31

Analysis of the Incidence of Expression of Tumor Antigens in Pathologically Proven Stage I, II and III Non-Small Cell Lung Cancer(NSCLC) in Asiatic Patients

CompletedNCT01837511

GlaxoSmithKlinePathologically Proven Stage I, II and III Non-Small Cell Lung Cancer (NSCLC)

Start: 2007-08-31End: 2008-01-31Updated: 2013-04-23

Related Papers

The prevalence of expression of MAGE-A3 and PRAME tumor antigens in East and South East Asian non-small cell lung cancer patients.

2016-10-0522 citations